Perspective - (2025) Volume 10, Issue 6
Received: 01-Dec-2025, Manuscript No. jomp-26-185137;
Editor assigned: 03-Dec-2025, Pre QC No. P-185137;
Reviewed: 17-Dec-2025, QC No. Q-185137;
Revised: 22-Dec-2025, Manuscript No. R-185137;
Published:
29-Dec-2025
, DOI: 10.37421/2576-3857.2025.10.339
Citation: Oliveira, Gabriela. ”Epigenetic Therapies: Targeting Glioblastoma Growth and Resistance.” J Oncol Med and Pract 10 (2025):339.
Copyright: v© 2025 Oliveira G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The field of glioblastoma (GBM) therapy is actively exploring epigenetic regulators as promising therapeutic targets. These regulators, including DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and lysine-specific demethylases (LSDs), play crucial roles in GBM pathogenesis by altering gene expression patterns that drive tumor growth, invasion, and therapeutic resistance. Inhibiting these epigenetic enzymes can potentially re-sensitize GBM cells to conventional treatments like chemotherapy and radiotherapy, and even directly induce tumor cell death. Research is focused on developing novel small molecules and combination strategies that effectively target these epigenetic pathways, aiming to overcome the significant clinical challenges associated with GBM [1].
Histone deacetylase (HDAC) inhibitors represent a significant class of epigenetic drugs being investigated for glioblastoma. By increasing histone acetylation, these agents can promote the expression of tumor suppressor genes and induce apoptosis in cancer cells. Several HDAC inhibitors are in clinical trials for GBM, often in combination with standard therapies. Understanding the specific HDAC isoforms involved in GBM and tailoring inhibitor selection are key to optimizing efficacy and minimizing toxicity [2].
DNA methyltransferase (DNMT) inhibitors, such as azacytidine and decitabine, are being explored for their potential to reverse aberrant DNA methylation patterns in glioblastoma. These epigenetic alterations can silence critical genes involved in cell cycle control and differentiation. While these drugs have shown efficacy in other hematological malignancies, their application in GBM is still under investigation, with a focus on overcoming resistance mechanisms and identifying patient subgroups that might benefit most [3].
Lysine-specific demethylase 1 (LSD1) is another epigenetic regulator implicated in glioblastoma progression. Inhibition of LSD1 has shown promise in preclinical models by affecting cell differentiation and proliferation. The development of specific LSD1 inhibitors for GBM therapy is an active area of research, aiming to exploit its role in maintaining the aggressive phenotype of these tumors. Combination therapies are also being explored to enhance the therapeutic impact of LSD1 inhibition [4].
The intricate interplay between different epigenetic modifiers in glioblastoma presents opportunities for combinatorial therapeutic approaches. Targeting multiple epigenetic pathways simultaneously may overcome resistance mechanisms that often emerge with single-agent treatments. Research is investigating combinations of DNMT inhibitors, HDAC inhibitors, and other epigenetic modulators, as well as their integration with conventional therapies, to achieve more durable responses in GBM patients [5].
The tumor microenvironment in glioblastoma significantly influences therapeutic responses. Epigenetic regulators can modulate the interactions between tumor cells and the surrounding stromal and immune cells. Understanding how epigenetic modifications impact the GBM microenvironment, such as through the regulation of immune checkpoints or the secretion of cytokines, is crucial for designing effective epigenetic-based immunotherapies or combination strategies [6].
Resistance to standard glioblastoma treatments, including radiotherapy and temozolomide, is a major hurdle. Epigenetic mechanisms are increasingly recognized as key drivers of this resistance. Strategies targeting epigenetic regulators aim to overcome these acquired or intrinsic resistance phenotypes by restoring sensitivity to conventional therapies. This involves identifying the specific epigenetic alterations that confer resistance and developing drugs that can effectively reverse them [7].
Biomarkers for predicting response to epigenetic therapies in glioblastoma are crucial for patient stratification and personalized treatment. Identifying specific epigenetic marks or the expression levels of epigenetic regulators that correlate with therapeutic efficacy can guide clinical decision-making. Ongoing research is focused on developing reliable epigenetic biomarkers that can help select patients most likely to benefit from these novel therapeutic strategies [8].
The development of novel epigenetic drugs with improved specificity and reduced toxicity is essential for advancing glioblastoma therapy. Current research focuses on designing next-generation inhibitors that can selectively target specific isoforms of epigenetic enzymes or exploit unique vulnerabilities in GBM cells. These efforts aim to enhance therapeutic efficacy while minimizing off-target effects and improving the overall safety profile of epigenetic treatments [9].
Pharmacological targeting of bromodomain and extraterminal domain (BET) proteins, which are key epigenetic readers, is an emerging strategy in glioblastoma research. BET inhibitors can disrupt the transcriptional programs that drive GBM proliferation and survival. Preclinical studies have demonstrated the potential of BET inhibitors, both as single agents and in combination therapies, to suppress tumor growth and overcome resistance [10].
The field of glioblastoma (GBM) therapy is actively exploring epigenetic regulators as promising therapeutic targets. These regulators, including DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and lysine-specific demethylases (LSDs), play crucial roles in GBM pathogenesis by altering gene expression patterns that drive tumor growth, invasion, and therapeutic resistance. Inhibiting these epigenetic enzymes can potentially re-sensitize GBM cells to conventional treatments like chemotherapy and radiotherapy, and even directly induce tumor cell death. Research is focused on developing novel small molecules and combination strategies that effectively target these epigenetic pathways, aiming to overcome the significant clinical challenges associated with GBM [1].
Histone deacetylase (HDAC) inhibitors represent a significant class of epigenetic drugs being investigated for glioblastoma. By increasing histone acetylation, these agents can promote the expression of tumor suppressor genes and induce apoptosis in cancer cells. Several HDAC inhibitors are in clinical trials for GBM, often in combination with standard therapies. Understanding the specific HDAC isoforms involved in GBM and tailoring inhibitor selection are key to optimizing efficacy and minimizing toxicity [2].
DNA methyltransferase (DNMT) inhibitors, such as azacytidine and decitabine, are being explored for their potential to reverse aberrant DNA methylation patterns in glioblastoma. These epigenetic alterations can silence critical genes involved in cell cycle control and differentiation. While these drugs have shown efficacy in other hematological malignancies, their application in GBM is still under investigation, with a focus on overcoming resistance mechanisms and identifying patient subgroups that might benefit most [3].
Lysine-specific demethylase 1 (LSD1) is another epigenetic regulator implicated in glioblastoma progression. Inhibition of LSD1 has shown promise in preclinical models by affecting cell differentiation and proliferation. The development of specific LSD1 inhibitors for GBM therapy is an active area of research, aiming to exploit its role in maintaining the aggressive phenotype of these tumors. Combination therapies are also being explored to enhance the therapeutic impact of LSD1 inhibition [4].
The intricate interplay between different epigenetic modifiers in glioblastoma presents opportunities for combinatorial therapeutic approaches. Targeting multiple epigenetic pathways simultaneously may overcome resistance mechanisms that often emerge with single-agent treatments. Research is investigating combinations of DNMT inhibitors, HDAC inhibitors, and other epigenetic modulators, as well as their integration with conventional therapies, to achieve more durable responses in GBM patients [5].
The tumor microenvironment in glioblastoma significantly influences therapeutic responses. Epigenetic regulators can modulate the interactions between tumor cells and the surrounding stromal and immune cells. Understanding how epigenetic modifications impact the GBM microenvironment, such as through the regulation of immune checkpoints or the secretion of cytokines, is crucial for designing effective epigenetic-based immunotherapies or combination strategies [6].
Resistance to standard glioblastoma treatments, including radiotherapy and temozolomide, is a major hurdle. Epigenetic mechanisms are increasingly recognized as key drivers of this resistance. Strategies targeting epigenetic regulators aim to overcome these acquired or intrinsic resistance phenotypes by restoring sensitivity to conventional therapies. This involves identifying the specific epigenetic alterations that confer resistance and developing drugs that can effectively reverse them [7].
Biomarkers for predicting response to epigenetic therapies in glioblastoma are crucial for patient stratification and personalized treatment. Identifying specific epigenetic marks or the expression levels of epigenetic regulators that correlate with therapeutic efficacy can guide clinical decision-making. Ongoing research is focused on developing reliable epigenetic biomarkers that can help select patients most likely to benefit from these novel therapeutic strategies [8].
The development of novel epigenetic drugs with improved specificity and reduced toxicity is essential for advancing glioblastoma therapy. Current research focuses on designing next-generation inhibitors that can selectively target specific isoforms of epigenetic enzymes or exploit unique vulnerabilities in GBM cells. These efforts aim to enhance therapeutic efficacy while minimizing off-target effects and improving the overall safety profile of epigenetic treatments [9].
Pharmacological targeting of bromodomain and extraterminal domain (BET) proteins, which are key epigenetic readers, is an emerging strategy in glioblastoma research. BET inhibitors can disrupt the transcriptional programs that drive GBM proliferation and survival. Preclinical studies have demonstrated the potential of BET inhibitors, both as single agents and in combination therapies, to suppress tumor growth and overcome resistance [10].
Epigenetic regulators are being investigated as novel therapeutic targets for glioblastoma (GBM). These regulators, including DNMTs, HDACs, and LSDs, influence gene expression patterns critical for tumor growth and resistance. Inhibiting them may re-sensitize GBM cells to conventional treatments or induce cell death. Specific classes of epigenetic drugs like HDAC inhibitors and DNMT inhibitors are undergoing clinical trials for GBM, with research focusing on optimizing their use and overcoming resistance. LSD1 inhibitors and BET protein inhibitors are also emerging as promising avenues. Combinatorial approaches targeting multiple epigenetic pathways are being explored to enhance efficacy and overcome resistance mechanisms. Furthermore, understanding the epigenetic regulation of the GBM tumor microenvironment is crucial for developing effective immunotherapies. The identification of reliable biomarkers is essential for patient stratification and personalized treatment strategies. The development of next-generation epigenetic drugs with improved specificity and reduced toxicity remains a key focus for advancing GBM therapy.
None
None
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report
